Scheduled Birth at Term for the Prevention of Pre-eclampsia (PREVENT-PE): An Open-Label Randomized Controlled Trial
( Lancet . 2026;407(10523):67–77. doi: 10.1016/S0140-6736(25)01207-3) Preeclampsia (PEC) is a leading cause of maternal morbidity and mortality worldwide and represents a significant health care burden; an estimated 75% of PEC cases occur at 37 weeks of gestation or greater. The risk for preterm PEC can be identified using the Fetal Medicine Foundation (FMF) competing risks model between 11 and 13 weeks of gestation, and prophylactic treatment with aspirin can prevent more than half of cases with elevated risk. Though assessments and biomarkers can often effectively identify individuals who will develop PEC, there are no proven interventions for preventing PEC that occurs at or near term. One possibility for intervention is planned early term delivery at 39 weeks, which previous literature has shown to reduce the number of cesarean deliveries (CDs) and the rates of other adverse outcomes. This study was designed to assess whether screening at 36 weeks gestation for PEC risk and offering risk-stratified, planned early term delivery would reduce the incidence of PEC.
Authors
- KH Nicolaides
- R Akolekar
- A Wright
- S Webster
- A Syngelaki
- J Goadsby
- LA Magee
- D Wright
- P von Dadelszen
Publication Details
- Journal
- Obstetric Anesthesia Digest
- Published
- 2026-11-18
- DOI
- https://doi.org/10.1097/01.aoa.0001288936.15779.e4
- Primary Topic
- Pregnancy and preeclampsia studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00